Allergy Diagnostics Market Size To Reach $16.37 Billion By 2033

May 2026 | Report Format: Electronic (PDF)

Allergy Diagnostics Market Growth & Trends

The global allergy diagnostics market size is estimated to reach USD 16.37 billion by 2033, registering a CAGR of 11.29% from 2026 to 2033, according to a new report by Grand View Research, Inc. Allergies continue to be a significant public health concern in the U.S. and worldwide, affecting both children and adults across all demographics. According to the CDC’s 2023 National Health Interview Survey (NHIS), approximately 25.7% of adults and 18.9% of children in the U.S. reported being diagnosed with seasonal allergies, eczema, or food allergies. This data highlights the growing prevalence of allergic conditions, reflecting an urgent need for better diagnostic tools and early detection strategies to reduce complications and improve quality of life.

Additionally, statistics from the Allergy & Asthma Network reveal that over 50 million Americans suffer from allergies each year, making them the sixth leading cause of chronic illness in the U.S. Food allergies alone affect an estimated 5.6 million children (around one in 13), and about 26 million adults further underlining the need for precise and accessible diagnostic solutions. Moreover, asthma, which is often triggered by allergens, affects more than 25 million Americans, including 4.2 million children. These figures point to the growing healthcare burden of allergic diseases and support the case for investments in advanced diagnostics and early intervention.

U.S. Demographic Variations:

Adults:

Non-Hispanic White adults were more likely to have seasonal allergies (28.4%) compared to Non-Hispanic Black (24%), Hispanic (18.8%), and Non-Hispanic Asian (17%) adults.
Eczema prevalence was higher among women (8.9%) than men (5.7%).
Non-Hispanic Black adults had a higher prevalence of food allergies (8.5%) compared to Hispanic (4.4%), Non-Hispanic White (6.2%), and Non-Hispanic Asian (4.5%) adults.

Children:

Boys (20%) were more likely to have seasonal allergies than girls (17.7%).
Children aged 6-11 years had the highest prevalence of eczema (12.1%), followed by those aged 0-5 years (10.4%), and 12-17 years (9.8%).
Non-Hispanic Black children were more likely to have food allergies (7.6%) compared to Hispanic (5%) and Non-Hispanic White (5.3%) children

The economic impact of allergic diseases is also substantial, costing the U.S. healthcare system billions annually due to emergency visits, hospitalizations, and lost productivity. The combination of rising prevalence, healthcare costs, and the risk of severe allergic reactions has created a compelling market demand for innovative allergy diagnostics that can offer accuracy, speed, and accessibility across various settings, from primary care to specialty clinics and even at-home testing kits.

Some of the key players in the global allergy diagnostics market include Thermo Fisher Scientific, Inc., HYCOR Biomedical, EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.), Omega Diagnostics Group PLC, Lincoln Diagnostics, Inc., AESKU.GROUP GmbH, Minaris Medical America, Inc., HOB Biotech Group Corp., Ltd., DASIT Group SPA, R-Biopharm AG, bioMérieux, and Siemens Healthcare GmbH.

These companies are actively engaged in strategic initiatives such as new product launches, regulatory approvals, and technology advancements to strengthen their global market presence and expand their allergy testing portfolios. For instance, in May 2022, Thermo Fisher Scientific expanded its allergy diagnostics offering in the U.S. by launching its Phadia 2500+ series for high-throughput in vitro allergy and autoimmune testing, enhancing lab efficiency and precision diagnostics. This launch supports the growing demand for comprehensive allergy panels and molecular-level testing, addressing increasing cases of food and respiratory allergies, particularly in aging and pediatric populations across key markets like the U.S. and Europe.

key Request a free sample copy or view report summary: Allergy Diagnostics Market Report

Allergy Diagnostics Market Report Highlights

By product and services, the consumables held the largest share of 63.42% of the market in 2025. This segment comprises critical components such as allergen extracts, assay kits, and reagents that are indispensable for both in vitro and in vivo testing.
By allergen, the inhaled allergen type accounted for the largest revenue share of the market in 2025, driven by the high prevalence of conditions such as asthma, allergic rhinitis, and allergic conjunctivitis caused by allergens like pollen, dust mites, and mold spores.
By test type, the In Vitro Test dominated the market in 2025, propelled by its convenience, reproducibility, and safety, particularly in patients where skin tests may pose risks.
By end-use, the hospitals & clinics accounted for the largest revenue share of the market in 2025. These settings are central to allergy diagnosis, management, and treatment planning, offering both diagnostic services and immunotherapy interventions under one roof.
North America dominated the allergy diagnostics market and accounted for a 36.62% share in 2025, supported by the rising prevalence of food allergies, allergic rhinitis, asthma, and atopic dermatitis across the United States and Canada.